Hypnotics

BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety

Retrieved on: 
Thursday, July 22, 2021
Psychoactive drugs, GABAA receptor positive allosteric modulators, Hypnotics, Muscle relaxants, Sedatives, Anxiolytic, Neurochemistry, Benzodiazepine

TD-010 or dihydrohonokiol-B (DHH-B) is a compound that BetterLife is developing primarily for benzodiazepine dependency in addition to anxiety.

Key Points: 
  • TD-010 or dihydrohonokiol-B (DHH-B) is a compound that BetterLife is developing primarily for benzodiazepine dependency in addition to anxiety.
  • We thank Mitacs for the funding and Carleton Universitys team, headed by Dr. Argel Aguilar-Valles at the Department of Neuroscience, for being an ideal partner to help us realize this vision."
  • The high rate of resistance to benzodiazepine and SSRIs for chronic anxiety disorder indicates an urgent unmet need for alternative anxiolytic treatments.
  • Mitacs is a not-for-profit organization that fosters growth and innovation in Canada by solving business challenges with research solutions from academic institutions.

Breckenridge Pharmaceutical, Inc. Announces Launch of Zolpidem Tartrate Extended-Release Tablets, USP (generic for Ambien® CR)

Retrieved on: 
Thursday, July 8, 2021
GABAA receptor positive allosteric modulators, Hypnotics, Imidazopyridines, Nonbenzodiazepines, Sanofi, Zolpidem

BERLIN, Conn., July 8, 2021 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc.announced today that it has launched Zolpidem Tartrate Extended-Release Tablets, USP (generic for Ambien CR), manufactured by Centaur Pharmaceuticals Pvt.

Key Points: 
  • BERLIN, Conn., July 8, 2021 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc.announced today that it has launched Zolpidem Tartrate Extended-Release Tablets, USP (generic for Ambien CR), manufactured by Centaur Pharmaceuticals Pvt.
  • Ltd. Breckenridge will market the product in its own label and offer 6.25 mg and 12.5 mg strengths in bottles of 100.
  • According to industry sales data, Ambien CR and its generics had annual sales of $42 million during the twelve months ending May 2021.
  • The U.S. Food and Drug Administration previously granted final approval of this product's Abbreviated New Drug Application.

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Retrieved on: 
Wednesday, June 9, 2021
Chemical compounds, Psychoactive drugs, Branches of biology, Hypnotics, GABAA receptor positive allosteric modulators, Pyridines, Orexin antagonist, G protein-coupled receptors, Acetamides, Lemborexant, Orexin receptor, Zolpidem

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

North America Cough Syrup Market Report 2021: Increasing Cases of Respiratory Issues are Providing Lucrative Opportunities - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021
Health, Pharmaceutical, Antitussives, Psychoactive drugs, Opioids, Drug culture, Hypnotics, Lean, Cold medicine, Cough, Drugs, Air pollution, Economic growth, Clinical medicine

b'The "North America Cough Syrup Market By Product, By Age Group, By Distribution Channel, By Country, Growth Potential, Industry Analysis Report and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe increasing cases of respiratory issues are providing lucrative opportunities for the cough syrup market.

Key Points: 
  • b'The "North America Cough Syrup Market By Product, By Age Group, By Distribution Channel, By Country, Growth Potential, Industry Analysis Report and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe increasing cases of respiratory issues are providing lucrative opportunities for the cough syrup market.
  • Moreover, the rising population of old age people along with increasing air pollution are driving the growth of the market.
  • However, the misuse of cough syrup coupled with the strict rules & regulations by the government will restrict the market growth.
  • Moreover, the increasing disposable income of people in emerging nations will also contribute to the rising growth of the global cough syrups market.

Europe Cough Syrup Market Analysis and Forecast, 2020-2021 & Forecast to 2026 with Germany Dominating - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021
Medical Supplies, Health, Antitussives, Psychoactive drugs, Opioids, Drug culture, Hypnotics, Lean, Articles, Cold medicine, Drugs, Distribution

b'The "Europe Cough Syrup Market By Product, By Age Group, By Distribution Channel, By Country, Growth Potential, Industry Analysis Report and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe Germany market dominated the Europe Pediatric Market by Country in 2019, growing at a CAGR of 5.7 % during the forecast period.

Key Points: 
  • b'The "Europe Cough Syrup Market By Product, By Age Group, By Distribution Channel, By Country, Growth Potential, Industry Analysis Report and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe Germany market dominated the Europe Pediatric Market by Country in 2019, growing at a CAGR of 5.7 % during the forecast period.
  • In addition, the ever-growing enhancements in products are projected to provide new growth prospects for the cough syrup market.\nThe increasing cases of respiratory issues are providing lucrative opportunities for the cough syrup market.
  • However, the misuse of cough syrup coupled with the strict rules & regulations by the government will restrict the market growth.
  • On the other hand, the high market potential of the developing regions will garner more growth opportunities for the cough syrup market growth.\nThe Retail Pharmacy market dominated the Spain Cough Syrup Market by Distribution Channel in 2019, thereby, achieving a market value of $85.9 million by 2026.

VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Cell signaling, GABAA receptor positive allosteric modulators, Pherine, Steroids, PH10, Hypnotics, Psychoactive drugs, Benzodiazepine, Antidepressant, GABA receptor

Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors.

Key Points: 
  • Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors.
  • In September 2020, the U.S. Food and Drug Administration (FDA) released a Drug Safety Communication (DSC) detailing the risks associated with use of benzodiazepines.
  • PH10 is a new generation antidepressant with a mechanism of action that is designed to be fundamentally different from all current FDA-approved antidepressants.
  • PH10 is a Phase 2 investigational pherine nasal spray designed to have rapid-onset effects and therapeutic potential in several neuropsychiatric indications involving depression.

FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia

Retrieved on: 
Wednesday, March 10, 2021
Chemical compounds, Branches of biology, Organic compounds, Chloroarenes, Hypnotics, Sedatives, GABAA receptor positive allosteric modulators, Lactams, Orexin, Daridorexant, Insomnia, Somnolence

The incidence of somnolence was low and did not increase with daridorexant 50 mg compared to placebo.

Key Points: 
  • The incidence of somnolence was low and did not increase with daridorexant 50 mg compared to placebo.
  • Patients reported no next-morning sleepiness compared to placebo as assessed by the morning visual analogue scale (VAS).
  • In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia.
  • Daridorexant is a dual orexin receptor antagonist (DORA) designed and developed for the treatment of insomnia.

High Prescription of Psychoactive Class of Medicines for Mental Health Conditions spurs Growth in Benzodiazepine Drugs Market, Market Projected to touch Valuation of US$ 2.617 billion by 2026, TMR

Retrieved on: 
Thursday, March 4, 2021
GABAA receptor positive allosteric modulators, Psychoactive drugs, Hypnotics, Benzodiazepine, Sedatives, Benzodiazepines, Chemical compounds, Neurochemistry

Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.

Key Points: 
  • Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.
  • In 2017, the global benzodiazepine drugs market was estimated to be worth around US $ 2055 Mn.
  • The market is projected to clock a growth rate of 2.7 % CAGR over the assessment tenure, from 2018 to 2026.
  • The global benzodiazepine drugs market is being driven by an increase in the prevalence of anxiety and seizures.

High Prescription of Psychoactive Class of Medicines for Mental Health Conditions spurs Growth in Benzodiazepine Drugs Market, Market Projected to touch Valuation of US$ 2.617 billion by 2026, TMR

Retrieved on: 
Thursday, March 4, 2021
GABAA receptor positive allosteric modulators, Psychoactive drugs, Hypnotics, Benzodiazepine, Sedatives, Benzodiazepines, Chemical compounds, Neurochemistry

Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.

Key Points: 
  • Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.
  • In 2017, the global benzodiazepine drugs market was estimated to be worth around US $ 2055 Mn.
  • The market is projected to clock a growth rate of 2.7 % CAGR over the assessment tenure, from 2018 to 2026.
  • The global benzodiazepine drugs market is being driven by an increase in the prevalence of anxiety and seizures.

Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Receptor agonists, Neurochemistry, GABAA receptor positive allosteric modulators, Drinking culture, Sedatives, Hypnotics, General anesthetics, Alcohol, Allosteric modulator, gamma-Aminobutyric acid, Allosteric regulation

ADX71441 potently decreased binge-like drinking, reduced relapse-like drinking, and dose-dependently reduced alcohol self-administration as well as decreasing motivation to consume alcohol.

Key Points: 
  • ADX71441 potently decreased binge-like drinking, reduced relapse-like drinking, and dose-dependently reduced alcohol self-administration as well as decreasing motivation to consume alcohol.
  • Augier E. (2021) Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder.
  • (2014) Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice.
  • (2017) The GABAB positive allosteric modulator ADX71441 attenuates alcohol self-administration and relapse to alcohol seeking in rats.